Clinical trial – www.brainwork.md

30th November 2018

Gene therapy shows promise in Parkinson’s disease

https://www.brainwork.md/content/uploads/2018/11/Brainwork-ParkinsonsPromise.jpg 2100 1400 Mea Holm, PhD Mea Holm, PhD https://secure.gravatar.com/avatar/7a927c1dcef51229f6403ce27328c69e?s=96&d=mm&r=g 30th November 2018 30th November 2018

Interim results from a Phase Ib trial show that gene therapy may reduce the need for medication in patients with Parkinson’s disease refractory to levodopa. The investigational therapy is designed…

Mea Holm, PhD
0
0

16th October 2018

Serum neurofilament light: A biomarker for disease activity in MS

https://www.brainwork.md/content/uploads/2018/10/MPR425-Brainwork-illustration-soluble-biomarkers-V00-03-20181012.jpg 1920 1080 Mea Holm, PhD Mea Holm, PhD https://secure.gravatar.com/avatar/7a927c1dcef51229f6403ce27328c69e?s=96&d=mm&r=g 16th October 2018 19th October 2018

How close are we to establishing a reliable liquid biomarker for detecting disease onset, progression and treatment response in multiple sclerosis? According to Dr Peter Calabresi (Johns Hopkins, USA) at…

Mea Holm, PhD
0
0

15th October 2018

Results from the MS-SMART trial unveiled

https://www.brainwork.md/content/uploads/2018/10/Brainwork-ECTRIMSSMART.jpg 3971 2975 Mea Holm, PhD Mea Holm, PhD https://secure.gravatar.com/avatar/7a927c1dcef51229f6403ce27328c69e?s=96&d=mm&r=g 15th October 2018 15th October 2018

Secondary progressive multiple sclerosis (SPMS) is known to be extremely difficult to treat; there are no effective therapies for halting or reversing disability progression in the late disease phase. In…

Mea Holm, PhD
0
0

11th October 2018

FLOODLIGHT offers illuminating outcomes for smartphone monitoring in MS

https://www.brainwork.md/content/uploads/2018/10/MPR425-Brainwork-illustrations-articles-Floodlight-V00-01-20181011-01-1.jpg 1920 1080 Peter Stevenson, PhD Peter Stevenson, PhD https://secure.gravatar.com/avatar/c5331bc85b1dc3f9749cac7354ddaaad?s=96&d=mm&r=g 11th October 2018 11th October 2018

Smartphone-based, high-yield active and passive self-monitoring of multiple sclerosis (MS) may enhance clinical disease assessments when compared to conventional methods for detecting subtle progressive clinical changes, according to a study…

Peter Stevenson, PhD
1
0

1st October 2018

Restoring “conductor” cells in the orchestra of schizophrenia

https://www.brainwork.md/content/uploads/2018/10/Brainwork-Orchestra.jpg 2850 1900 Peter Stevenson, PhD Peter Stevenson, PhD https://secure.gravatar.com/avatar/c5331bc85b1dc3f9749cac7354ddaaad?s=96&d=mm&r=g 1st October 2018 1st October 2018

Key symptoms of schizophrenia, including hallucinations, hyperactivity and impaired memory, could be caused by desynchronised cells in the brain, recent research published in Nature Neuroscience has revealed. The authors investigated…

Peter Stevenson, PhD
0
1

19th September 2018

Quarterly migraine injection approved in US

https://www.brainwork.md/content/uploads/2018/09/Brainwork-FDAApprovesMigraine.jpg 2885 1900 Peter Stevenson, PhD Peter Stevenson, PhD https://secure.gravatar.com/avatar/c5331bc85b1dc3f9749cac7354ddaaad?s=96&d=mm&r=g 19th September 2018 19th September 2018

The US FDA has approved a new humanised monoclonal antibody for migraine prevention in adults. Fremanezumab-vfrm – under the brand name AJOVYTM (Teva Pharmaceuticals) – prevents the interaction between calcitonin…

Peter Stevenson, PhD
1
0

2nd August 2018

Opticians could keep a closer eye on dementia

https://www.brainwork.md/content/uploads/2018/08/Brainwork-OpticiansCouldKeep.jpg 2704 1800 Peter Stevenson, PhD Peter Stevenson, PhD https://secure.gravatar.com/avatar/c5331bc85b1dc3f9749cac7354ddaaad?s=96&d=mm&r=g 2nd August 2018 13th August 2018

Routine retinal tests performed by opticians could help to identify those at risk of developing dementia, a new study reports. The scans – normally used to evaluate the integrity of…

Peter Stevenson, PhD
0
0

5th July 2018

Deep brain stimulation effective in early Parkinson’s tremors

https://www.brainwork.md/content/uploads/2018/07/Brainwork-Parkinsons.jpg 1600 1067 Peter Stevenson, PhD Peter Stevenson, PhD https://secure.gravatar.com/avatar/c5331bc85b1dc3f9749cac7354ddaaad?s=96&d=mm&r=g 5th July 2018 13th July 2018

Deep brain stimulation (DBS) could slow the progression of tremors in Parkinson’s disease (PD), according to new data from a pilot trial.1 Researchers at the Vanderbilt University Medical Center (Nashville,…

Peter Stevenson, PhD
0
0

20th June 2018

Rasagiline add-on treatment may offer hope to fast-progressing ALS patients

https://www.brainwork.md/content/uploads/2018/06/MPR425-Brainwork-illustration-brainlines-V00-01-20180619_3_light.gif 8001 4501 Mea Holm, PhD Mea Holm, PhD https://secure.gravatar.com/avatar/7a927c1dcef51229f6403ce27328c69e?s=96&d=mm&r=g 20th June 2018 13th July 2018

At the ‘late breaking’ session of the EAN 2018 congress, Professor Albert Ludolph from Ulm University (Germany) unveiled the results of a recent double-blind, randomised Phase II trial of rasagiline…

Mea Holm, PhD
0
0

20th June 2018

Revolutionary therapies could make spinal muscular atrophy a distant memory

https://www.brainwork.md/content/uploads/2018/06/MPR425-Brainwork-illustration-DNA-collage-V00-00-20180619.jpg 1200 675 Peter Stevenson, PhD Peter Stevenson, PhD https://secure.gravatar.com/avatar/c5331bc85b1dc3f9749cac7354ddaaad?s=96&d=mm&r=g 20th June 2018 13th July 2018

Cutting-edge molecular and genetic therapies for neurogenic disorders took centre stage at the EAN congress, with novel therapies showcased for the treatment of spinal muscular atrophy (SMA) – a severe…

Peter Stevenson, PhD
0
0